Alcon CEO and leadership

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX).

David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

My name is Sue Jean Lin. I am an accomplished global business leader across a diverse set of corporate functions including information technology, finance, cyber security, risk management, and digital transformation. I possess deep strategic and operational leadership experience and have demonstrated ability to drive higher business performance. My career in the life sciences industry spans over 30 years where I have driven enterprise growth and business turnarounds. I am a trusted advisor to Fortune 500 C-suites and board members. I am passionate about making a difference to customers. By focusing on “what’s making the business and customer successful”, I have led the development of strategy, technology implementation, and digital transformation that delivered growth and sustained changes for global pharmaceutical and medical device companies. I am a globalist, lived and worked in multiple continents.While my broad business experience is what mostly helped me to succeed, listening to the business, customers and end users has created greater access to intelligence and execution wisdom. My peers describe me as collaborative and outcome-driven colleague. My team sees me as a visionary, inspiring and supportive leader.

Experienced global human resources executive with expertise in culture transformation, compensation and benefits, and mergers and acquisitions across healthcare, industrial, financial services and technology industries. Deliver innovative and elegant solutions for company and customer challenges. Adept in compensation committee governance and executive compensation program design.

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX).

David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.